FindTrial
Sign In

Randomized and prospective clinical study of a new scheme based on voronorasen for eradication of Helicobacter pylori

Randomized and prospective clinical study of a new scheme based on voronorasen for eradication of Helicobacter pylori

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066677
Enrollment
Unknown
Registered
2022-12-13
Start date
2022-12-20
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori

Interventions

Test group:Vonorazone+amoxicillin (metronidazole)+clarithromycin
Control group:Standard quadruple scheme

Sponsors

Dongguan Songshan Lake Tungwah Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? Patients with confirmed Hp infection: positive breath test of carbon 13 ? Aged between 14 and 70

Exclusion criteria

Exclusion criteria: ? Serious adverse reactions occurred during drug administration, and the eradication program could not be effectively completed ? Failure to effectively follow up, recheck or lose follow-up after the end of eradication treatment ? Women with severe heart disease, chronic kidney disease, liver cirrhosis or pregnancy and lactation

Design outcomes

Primary

MeasureTime frame
Helicobacter pylori eradication rate;—

Countries

China

Contacts

Public ContactJiandong SU

Dongguan Songshan Lake Tungwah Hospital

stumsjd@163.com13712903007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026